Nicotinic acetylcholine receptor alpha-4 beta-2 and alpha-6 beta-2 subtypes (nAChR α4β2 and α6β2*)

The nicotinic acetylcholine receptor (nAChR) subtypes α4β2 and α6β2* are pentameric ligand-gated ion channels that serve as critical modulators of neurotransmission in the central nervous system [1, 3]. The α4β2 subtype is the most abundant high-affinity nicotinic receptor in the brain, playing a central role in cognitive functions such as attention and memory, as well as the mediation of nicotine's addictive properties [3, 6]. The α6β2* subtype is more restricted in its expression, primarily localized to dopaminergic neurons in the mesolimbic and nigrostriatal pathways, where it regulates dopamine release [1, 2]. These receptors are primary therapeutic targets for smoking cessation, with drugs like varenicline acting as partial agonists to reduce cravings and withdrawal symptoms while blocking the reinforcing effects of nicotine [4, 6]. Additionally, they are being investigated for their potential in treating neurodegenerative diseases like Parkinson's and Alzheimer's, as well as psychiatric conditions like schizophrenia and depression, due to their ability to modulate dopaminergic and cholinergic signaling [1, 3, 4].

Other names

α4β2* nAChR [3]α6β2* nAChR [1, 10]Neuronal nicotinic acetylcholine receptor [3, 7]High-affinity nicotine receptor [3, 12]CHRNA4/CHRNB2 receptor [6]CHRNA6/CHRNB2 receptor [10]

Partial agonism, full agonism, antagonism, and positive allosteric modulation [3, 4, 7].